Pharmosa Biopharm Inc. AI Stock Analysis
Pharmosa Biopharm Inc. (6875) AI Stock Analysis
Pharmosa Biopharm Inc.
(TPEx:6875)
The score is held at the low end primarily by deteriorating financial performance: revenue has declined two years running, gross margin turned negative, net losses nearly doubled, and free cash burn widened to -NT$476.8 million. A debt-free balance sheet (debt-to-equity 0.06, equity funding 89% of assets) provides a cushion, but equity shrank about 20% in 2025 and the current burn rate points to a need for additional funding and possible dilution. Technicals compound the picture, with the price below all key moving averages and negative MACD confirming a sustained downtrend, though the deeply oversold RSI and Stochastic readings leave room for a short-term bounce. Valuation offers no support given negative earnings and no dividend, leaving the investment case dependent on clinical pipeline milestones rather than current financials.
Pharmosa Biopharm Inc. (6875) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 148.70K
- Price to Earnings (P/E)
- -9.1
- Beta (1Y)
- 0.33
- Revenue Growth
- -69.26%
- EPS Growth
- -24.53%
- Country
- TW
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Pharmosa Biopharm Inc. Business Overview & Revenue Model
Company Description
Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy...
Pharmosa Biopharm Inc. Financial Statement Overview
Summary
Pharmosa shows the profile of a pre-commercial biotech under strain. Milestone-driven revenue fell for a second straight year to NT$67.3 million (-51%), gross margin swung negative to -23.4%, and the net loss nearly doubled to NT$383.8 million (Income Statement score 20). Cash generation is weaker still: operating cash flow of -NT$357.5 million and free cash flow of -NT$476.8 million mark the largest burn in six years, with negative free cash flow in every year presented (Cash Flow score 18). The offset is a solid, essentially debt-free balance sheet — debt-to-equity of 0.06 and equity funding about 89% of assets (Balance Sheet score 64) — though equity fell roughly 20% in 2025 and ROE is -24.6%, pointing to a limited runway and rising dilution risk.
Income Statement
20Very NegativeBalance Sheet
64PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.38M | 67.27M | 167.57M | 314.50M | 0 | 0 |
| Gross Profit | -19.94M | -15.75M | 126.90M | 314.50M | 0 | 0 |
| EBITDA | -342.88M | -371.37M | -140.38M | 34.63M | -257.08M | -244.13M |
| Net Income | -351.33M | -383.85M | -166.65M | 8.46M | -266.51M | -256.48M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.75B | 2.16B | 1.33B | 799.37M | 586.37M |
| Cash, Cash Equivalents and Short-Term Investments | 933.28M | 1.13B | 1.62B | 974.06M | 672.51M | 461.46M |
| Total Debt | 340.88M | 99.61M | 117.60M | 144.37M | 21.19M | 37.09M |
| Total Liabilities | 416.60M | 190.57M | 225.66M | 195.99M | 38.25M | 54.93M |
| Stockholders Equity | 1.37B | 1.56B | 1.94B | 1.14B | 761.12M | 531.43M |
Cash Flow | ||||||
| Free Cash Flow | -499.23M | -476.83M | -293.13M | -39.05M | -268.50M | -240.75M |
| Operating Cash Flow | -319.30M | -357.48M | -127.16M | 42.42M | -258.31M | -237.51M |
| Investing Cash Flow | 219.38M | 256.17M | -1.04B | -93.84M | -10.17M | 4.75M |
| Financing Cash Flow | 132.17M | -16.89M | 942.11M | 352.97M | 479.52M | 279.68M |
Pharmosa Biopharm Inc. Peers Comparison
Overall Rating
TW:649241Neutral- TW:687537Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6875 | Pharmosa Biopharm Inc. | 25.05 | -24.60 | -49.55% | |
| TW:4178 | Stemcyte International Ltd. | 15.95 | -6.45 | -28.79% | |
| TW:6492 | Senhwa Biosciences Inc | 30.10 | -13.07 | -30.28% | |
| TW:6838 | Formosa Pharmaceuticals, Inc. | 20.60 | -6.85 | -24.95% | |
| TW:6885 | BRIM Biotechnology, Inc. | 26.85 | -3.00 | -10.05% | |
| TW:7427 | Great Novel Therapeutics Biotech & Medicals Corp. | 59.50 | 21.41 | 56.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026